Molecular Determinants in the Bioactivation of the Dopaminergic Neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Overview

Journal J Comput Aided Mol Des

Publisher Springer

Specialties Biomedical Engineering
Molecular Biology

Date 1991 Oct 1

PMID 1685185

Citations 1

Authors

S M Efange

R J Boudreau

Affiliations

Soon will be listed here.

Abstract

Nineteen analogs of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) have been used as probes to study the structural parameters that influence MAO-catalyzed oxidation. In this study, the efficiency of enzyme-catalyzed substrate oxidation was found to be unrelated to parameters such as the ionization potential, dipole moment, net atomic charge at C5 and the dihedral angle between the phenyl ring and the tetrahydropyridine moiety. Conformational analysis revealed that substitution at the C2' position of MPTP yields atropisomers. It is suggested that one of these atropisomers would be either inactive or substantially less active than the other. Therefore, the relative oxidative efficiency and toxicity of these compounds reported earlier may have been significantly underestimated. Based on the conformational analysis and other data, a rudimentary model of the MAO substrate site has been developed which partially explains the substrate specificities of MAO A and MAO B. Each substrate binding site can be divided into two regions, (a) an amine-binding pocket (for the tetrahydropyridine moiety), and (b) a 'bulky substituent' region (for the phenyl group and its substituents). The length of the substrate binding site (measured along the long axis of MPTP) is approximately 8.5 A, and the width of the 'amine-binding' pocket is approximately 2.5 A (from C3 to C5). The 'bulky substituent' region contains a central area for binding the phenyl group of MPTP. This central area is flanked by two hydrophobic pockets, P2' and P3'. In MAO A, the pocket P2'-A is oriented 45-135 degrees relative to the plane of the tetrahydropyridine moiety, with a radius of 3.1 A from C2' of the phenyl ring. The radius of a similar but smaller pocket, P2'-B, in MAO B, is approximately 2.7 A. In MAO B, the pocket P3'-B (radius 2.36 A from C3') is larger than a similar pocket P3'-A (radius 1.70 A from C3') in MAO A. The foregoing characterization suggests that differences in the size and topography of both of the substituent pockets play an important role in determining the substrate specificities of these two isozymes.

Citing Articles

Kinetics, mechanism, and inhibition of monoamine oxidase.

Ramsay R, Albreht A J Neural Transm (Vienna). 2018; 125(11):1659-1683.

PMID: 29516165 DOI: 10.1007/s00702-018-1861-9.

References

Schultz W . MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology. Gen Pharmacol. 1988; 19(2):153-61. DOI: 10.1016/0306-3623(88)90055-9. View

SINGER T, Castagnoli Jr N, Ramsay R, TREVOR A . Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem. 1987; 49(1):1-8. DOI: 10.1111/j.1471-4159.1987.tb03384.x. View

Youngster S, Duvoisin R, Hess A, Sonsalla P, Kindt M, Heikkila R . 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice. Eur J Pharmacol. 1986; 122(2):283-7. DOI: 10.1016/0014-2999(86)90115-9. View

Johannessen J, Chiueh C, Burns R, Markey S . Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 1985; 36(3):219-24. DOI: 10.1016/0024-3205(85)90062-1. View

Snyder S, DAmato R . MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Neurology. 1986; 36(2):250-8. DOI: 10.1212/wnl.36.2.250. View

Riachi N, Arora P, Sayre L, Harik S . Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease. J Neurochem. 1988; 50(4):1319-21. DOI: 10.1111/j.1471-4159.1988.tb10610.x. View

Davis G, Williams A, Markey S, EBERT M, Caine E, Reichert C . Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979; 1(3):249-54. DOI: 10.1016/0165-1781(79)90006-4. View

Youngster S, Nicklas W, Heikkila R . Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of.... J Pharmacol Exp Ther. 1989; 249(3):829-35. View

Heikkila R, Kindt M, Sonsalla P, Giovanni A, Youngster S, McKeown K . Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A. 1988; 85(16):6172-6. PMC: 281927. DOI: 10.1073/pnas.85.16.6172. View

10.

TREVOR A, SINGER T, Ramsay R, Castagnoli Jr N . Processing of MPTP by monoamine oxidases: implications for molecular toxicology. J Neural Transm Suppl. 1987; 23:73-89. DOI: 10.1007/978-3-7091-8901-6_5. View

11.

Mayer R, Kindt M, Heikkila R . Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem. 1986; 47(4):1073-9. DOI: 10.1111/j.1471-4159.1986.tb00722.x. View

12.

Fuller R, Hemrick-Luecke S . Persistent depletion of striatal dopamine and its metabolites in mice by TMMP, an analogue of MPTP. J Pharm Pharmacol. 1987; 39(8):667-9. DOI: 10.1111/j.2042-7158.1987.tb03453.x. View

13.

Fuller R, Hemrick-Luecke S . Depletion of heart norepinephrine in mice by some analogs of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Res Commun Chem Pathol Pharmacol. 1987; 56(2):147-56. View

14.

Irwin I, Langston J . Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?. Life Sci. 1985; 36(3):207-12. DOI: 10.1016/0024-3205(85)90060-8. View

15.

Youngster S, Sonsalla P, Heikkila R . Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem. 1987; 48(3):929-34. DOI: 10.1111/j.1471-4159.1987.tb05606.x. View

16.

Bhatti A, Burdon J, Williams A, Pall H, Ramsden D . Synthesis and nuclear magnetic resonance spectroscopic, mass spectroscopic, and plasma amine oxidase inhibitory properties of analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem. 1988; 50(4):1097-104. DOI: 10.1111/j.1471-4159.1988.tb10578.x. View

17.

Langston J, Irwin I, Langston E, FORNO L . The importance of the '4-5' double bond for neurotoxicity in primates of the pyridine derivative MPTP. Neurosci Lett. 1984; 50(1-3):289-94. DOI: 10.1016/0304-3940(84)90501-9. View

18.

Gibb C, Willoughby J, Glover V, Sandler M, Testa B, Jenner P . Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary. Neurosci Lett. 1987; 76(3):316-22. DOI: 10.1016/0304-3940(87)90422-8. View

19.

Finnegan K, Irwin I, DELANNEY L, Ricaurte G, Langston J . 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Pharmacol Exp Ther. 1987; 242(3):1144-51. View

20.

Javitch J, DAmato R, Strittmatter S, Snyder S . Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A. 1985; 82(7):2173-7. PMC: 397515. DOI: 10.1073/pnas.82.7.2173. View